Table 3

Demographic and clinical features of patients with PsA, nonpsoriatic SpA and RA

Parameter

PsA

Nonpsoriatic SpA

RA

Number of patients

8

12

20

Sex (male/female)

4/4

9/3

8/12

Age (years)

45.1 ± 7.1

39.7 ± 8.9

58.9 ± 17.2

Disease duration (years)

6.0 ± 9.7

6.6 ± 6.0

4.5 ± 7.9

Number of swollen joints

3.0 ± 1.9

2.6 ± 3.1

11.7 ± 8.3

Serum CRP (mg/dl)

6.2 ± 6.5

4.3 ± 5.1

7.3 ± 7.4

ESR (mm/hour)

36.4 ± 34.7

23.8 ± 25.2

44.2 ± 28.9

Rheumatoid factor (+/-)

0/8

0/11

14/6

DMARD (+/-)

3/3

8/4

8/12

Corticosteroids (+/-)

1/5

0/12

9/11

The nonpsoriatic SpA subgroup includes six AS and six USpA patients. Values are expressed as mean ± standard deviation. AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid arthritis; USpA, undifferentiated spondyloarthropathy.

Kruithof et al. Arthritis Research & Therapy 2005 7:R569   doi:10.1186/ar1698